Prostate Cancer Diagnostics - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB503240515

Publication Date:

March 14, 2024

Pages:

113

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The prostate is a walnut-sized gland located behind the base of a man鈥檚 penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
The global market for Prostate Cancer Diagnostics was estimated to be worth US$ 13430 million in 2023 and is forecast to a readjusted size of US$ 22860 million by 2030 with a CAGR of 7.8% during the forecast period 2024-2030
麻豆原创 competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Prostate Cancer Diagnostics by region & country, by Type, and by Application.
The Prostate Cancer Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Diagnostics.
麻豆原创 Segmentation
By Company
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Segment by Type:
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segment by Application
Age Below 55
Age 55-75
Age Above 75
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Prostate Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Prostate Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Prostate Cancer Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Prostate Cancer Diagnostics Product Introduction
1.2 Global Prostate Cancer Diagnostics 麻豆原创 Size Forecast
1.3 Prostate Cancer Diagnostics 麻豆原创 Trends & Drivers
1.3.1 Prostate Cancer Diagnostics Industry Trends
1.3.2 Prostate Cancer Diagnostics 麻豆原创 Drivers & Opportunity
1.3.3 Prostate Cancer Diagnostics 麻豆原创 Challenges
1.3.4 Prostate Cancer Diagnostics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Prostate Cancer Diagnostics Players Revenue Ranking (2023)
2.2 Global Prostate Cancer Diagnostics Revenue by Company (2019-2024)
2.3 Key Companies Prostate Cancer Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Prostate Cancer Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Prostate Cancer Diagnostics
2.6 Prostate Cancer Diagnostics 麻豆原创 Competitive Analysis
2.6.1 Prostate Cancer Diagnostics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Prostate Cancer Diagnostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Diagnostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tumor Biomarker Tests
3.1.2 Imaging
3.1.3 Biopsy
3.1.4 Other
3.2 Global Prostate Cancer Diagnostics Sales Value by Type
3.2.1 Global Prostate Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Prostate Cancer Diagnostics Sales Value, by Type (2019-2030)
3.2.3 Global Prostate Cancer Diagnostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Age Below 55
4.1.2 Age 55-75
4.1.3 Age Above 75
4.2 Global Prostate Cancer Diagnostics Sales Value by Application
4.2.1 Global Prostate Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Prostate Cancer Diagnostics Sales Value, by Application (2019-2030)
4.2.3 Global Prostate Cancer Diagnostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Prostate Cancer Diagnostics Sales Value by Region
5.1.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Prostate Cancer Diagnostics Sales Value by Region (2019-2024)
5.1.3 Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030)
5.1.4 Global Prostate Cancer Diagnostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Prostate Cancer Diagnostics Sales Value, 2019-2030
5.2.2 North America Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Prostate Cancer Diagnostics Sales Value, 2019-2030
5.3.2 Europe Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Prostate Cancer Diagnostics Sales Value, 2019-2030
5.4.2 Asia Pacific Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Prostate Cancer Diagnostics Sales Value, 2019-2030
5.5.2 South America Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Prostate Cancer Diagnostics Sales Value, 2019-2030
5.6.2 Middle East & Africa Prostate Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Prostate Cancer Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Prostate Cancer Diagnostics Sales Value
6.3 United States
6.3.1 United States Prostate Cancer Diagnostics Sales Value, 2019-2030
6.3.2 United States Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Prostate Cancer Diagnostics Sales Value, 2019-2030
6.4.2 Europe Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Prostate Cancer Diagnostics Sales Value, 2019-2030
6.5.2 China Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Prostate Cancer Diagnostics Sales Value, 2019-2030
6.6.2 Japan Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Prostate Cancer Diagnostics Sales Value, 2019-2030
6.7.2 South Korea Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Prostate Cancer Diagnostics Sales Value, 2019-2030
6.8.2 Southeast Asia Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Prostate Cancer Diagnostics Sales Value, 2019-2030
6.9.2 India Prostate Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Prostate Cancer Diagnostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 OPKO
7.1.1 OPKO Profile
7.1.2 OPKO Main Business
7.1.3 OPKO Prostate Cancer Diagnostics Products, Services and Solutions
7.1.4 OPKO Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.1.5 OPKO Recent Developments
7.2 Genomic Health
7.2.1 Genomic Health Profile
7.2.2 Genomic Health Main Business
7.2.3 Genomic Health Prostate Cancer Diagnostics Products, Services and Solutions
7.2.4 Genomic Health Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.2.5 Genomic Health Recent Developments
7.3 Abbott
7.3.1 Abbott Profile
7.3.2 Abbott Main Business
7.3.3 Abbott Prostate Cancer Diagnostics Products, Services and Solutions
7.3.4 Abbott Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.3.5 Beckman Coulter Recent Developments
7.4 Beckman Coulter
7.4.1 Beckman Coulter Profile
7.4.2 Beckman Coulter Main Business
7.4.3 Beckman Coulter Prostate Cancer Diagnostics Products, Services and Solutions
7.4.4 Beckman Coulter Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.4.5 Beckman Coulter Recent Developments
7.5 Siemens Healthcare
7.5.1 Siemens Healthcare Profile
7.5.2 Siemens Healthcare Main Business
7.5.3 Siemens Healthcare Prostate Cancer Diagnostics Products, Services and Solutions
7.5.4 Siemens Healthcare Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.5.5 Siemens Healthcare Recent Developments
7.6 bioMeriux
7.6.1 bioMeriux Profile
7.6.2 bioMeriux Main Business
7.6.3 bioMeriux Prostate Cancer Diagnostics Products, Services and Solutions
7.6.4 bioMeriux Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.6.5 bioMeriux Recent Developments
7.7 Roche
7.7.1 Roche Profile
7.7.2 Roche Main Business
7.7.3 Roche Prostate Cancer Diagnostics Products, Services and Solutions
7.7.4 Roche Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.7.5 Roche Recent Developments
7.8 MDx Health
7.8.1 MDx Health Profile
7.8.2 MDx Health Main Business
7.8.3 MDx Health Prostate Cancer Diagnostics Products, Services and Solutions
7.8.4 MDx Health Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.8.5 MDx Health Recent Developments
7.9 DiaSorin
7.9.1 DiaSorin Profile
7.9.2 DiaSorin Main Business
7.9.3 DiaSorin Prostate Cancer Diagnostics Products, Services and Solutions
7.9.4 DiaSorin Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.9.5 DiaSorin Recent Developments
7.10 Myriad Genetics
7.10.1 Myriad Genetics Profile
7.10.2 Myriad Genetics Main Business
7.10.3 Myriad Genetics Prostate Cancer Diagnostics Products, Services and Solutions
7.10.4 Myriad Genetics Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.10.5 Myriad Genetics Recent Developments
7.11 Ambry Genetics
7.11.1 Ambry Genetics Profile
7.11.2 Ambry Genetics Main Business
7.11.3 Ambry Genetics Prostate Cancer Diagnostics Products, Services and Solutions
7.11.4 Ambry Genetics Prostate Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
7.11.5 Ambry Genetics Recent Developments
8 Industry Chain Analysis
8.1 Prostate Cancer Diagnostics Industrial Chain
8.2 Prostate Cancer Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Prostate Cancer Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Prostate Cancer Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.